12:00 AM
Jun 29, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RX-10001: Phase I started

Resolvyx began a double-blind, placebo-controlled, single and multiple ascending-dose Phase I trial to evaluate oral RX-10001 in 56...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >